Larbre B, Nicolas J F, Sarret Y, Tognet E, Mercatello A, Thivolet J
Clinique Dermatologique, Hôpital Edouard Herriot, Lyon.
Ann Dermatol Venereol. 1993;120(8):528-33.
The cutaneous manifestations which follow the administration of recombinant interleukin-2 (rIL-2) are well known, but their nature and severity have not yet been fully studied. The authors report the dermatological changes observed in 12 patients treated with rIL-2 for renal cancer. The predominant lesion was generalized erythema followed by desquamation.
